Cell membrane lipids as experimental therapeutic targets

Jerald J. Killion, Alan J. Schroit

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cell membranes contain numerous species of glycosphingolipids (GSL) and glycerophospholipids. Changes in the surface expression of these moieties that accompany malignant transformation are potential targets for immune therapies. There is increasing evidence that tumour specificity resides in the carbohydrate composition and topography of gangliosides and in the asymmetric distribution of phospholipids in the bilayer membrane. However, since these epitopes are not antigenic, circumvention of immunological tolerance to these self antigens is required to generate an effective immune response. New methodologies accomplish this by coupling these hapten-like lipid epitopes to immunogenic protein carriers. Indeed, the generation of immune responses to endogenous lipid antigens occurs in several autoimmune syndromes and may serve as natural models for therapeutic immune intervention that influence pathways critical to tumour angiogenesis, proliferation and apoptosis.

Original languageEnglish (US)
Pages (from-to)453-468
Number of pages16
JournalExpert Opinion on Therapeutic Targets
Volume3
Issue number3
DOIs
StatePublished - Sep 1 1999

Fingerprint

Membrane Lipids
Tumors
Epitopes
Glycerophospholipids
Lipids
Glycosphingolipids
Critical Pathways
Haptens
Gangliosides
Autoantigens
Cell membranes
Topography
Neoplasms
Phospholipids
Carrier Proteins
Carbohydrates
Cell Membrane
Apoptosis
Membranes
Antigens

Keywords

  • β2-glycoprotein 1
  • antiphospholipid syndrome
  • autoimmunity
  • cancer
  • gangliosides
  • lipid antigens
  • macrophages
  • phosphatidylserine

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Cell membrane lipids as experimental therapeutic targets. / Killion, Jerald J.; Schroit, Alan J.

In: Expert Opinion on Therapeutic Targets, Vol. 3, No. 3, 01.09.1999, p. 453-468.

Research output: Contribution to journalArticle

Killion, Jerald J. ; Schroit, Alan J. / Cell membrane lipids as experimental therapeutic targets. In: Expert Opinion on Therapeutic Targets. 1999 ; Vol. 3, No. 3. pp. 453-468.
@article{234cca82478c4f598dd6066802559f68,
title = "Cell membrane lipids as experimental therapeutic targets",
abstract = "Cell membranes contain numerous species of glycosphingolipids (GSL) and glycerophospholipids. Changes in the surface expression of these moieties that accompany malignant transformation are potential targets for immune therapies. There is increasing evidence that tumour specificity resides in the carbohydrate composition and topography of gangliosides and in the asymmetric distribution of phospholipids in the bilayer membrane. However, since these epitopes are not antigenic, circumvention of immunological tolerance to these self antigens is required to generate an effective immune response. New methodologies accomplish this by coupling these hapten-like lipid epitopes to immunogenic protein carriers. Indeed, the generation of immune responses to endogenous lipid antigens occurs in several autoimmune syndromes and may serve as natural models for therapeutic immune intervention that influence pathways critical to tumour angiogenesis, proliferation and apoptosis.",
keywords = "β2-glycoprotein 1, antiphospholipid syndrome, autoimmunity, cancer, gangliosides, lipid antigens, macrophages, phosphatidylserine",
author = "Killion, {Jerald J.} and Schroit, {Alan J.}",
year = "1999",
month = "9",
day = "1",
doi = "10.1517/14728222.3.3.453",
language = "English (US)",
volume = "3",
pages = "453--468",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Cell membrane lipids as experimental therapeutic targets

AU - Killion, Jerald J.

AU - Schroit, Alan J.

PY - 1999/9/1

Y1 - 1999/9/1

N2 - Cell membranes contain numerous species of glycosphingolipids (GSL) and glycerophospholipids. Changes in the surface expression of these moieties that accompany malignant transformation are potential targets for immune therapies. There is increasing evidence that tumour specificity resides in the carbohydrate composition and topography of gangliosides and in the asymmetric distribution of phospholipids in the bilayer membrane. However, since these epitopes are not antigenic, circumvention of immunological tolerance to these self antigens is required to generate an effective immune response. New methodologies accomplish this by coupling these hapten-like lipid epitopes to immunogenic protein carriers. Indeed, the generation of immune responses to endogenous lipid antigens occurs in several autoimmune syndromes and may serve as natural models for therapeutic immune intervention that influence pathways critical to tumour angiogenesis, proliferation and apoptosis.

AB - Cell membranes contain numerous species of glycosphingolipids (GSL) and glycerophospholipids. Changes in the surface expression of these moieties that accompany malignant transformation are potential targets for immune therapies. There is increasing evidence that tumour specificity resides in the carbohydrate composition and topography of gangliosides and in the asymmetric distribution of phospholipids in the bilayer membrane. However, since these epitopes are not antigenic, circumvention of immunological tolerance to these self antigens is required to generate an effective immune response. New methodologies accomplish this by coupling these hapten-like lipid epitopes to immunogenic protein carriers. Indeed, the generation of immune responses to endogenous lipid antigens occurs in several autoimmune syndromes and may serve as natural models for therapeutic immune intervention that influence pathways critical to tumour angiogenesis, proliferation and apoptosis.

KW - β2-glycoprotein 1

KW - antiphospholipid syndrome

KW - autoimmunity

KW - cancer

KW - gangliosides

KW - lipid antigens

KW - macrophages

KW - phosphatidylserine

UR - http://www.scopus.com/inward/record.url?scp=47749127544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47749127544&partnerID=8YFLogxK

U2 - 10.1517/14728222.3.3.453

DO - 10.1517/14728222.3.3.453

M3 - Article

AN - SCOPUS:47749127544

VL - 3

SP - 453

EP - 468

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 3

ER -